- Home
- |
- Contact
- |
- Pharmacovigilance
- |
Welcome to
Chiesi group
Parma (Italy) November 28, 2022 – On the International Day for the Elimination of Violence Against Women, Chiesi, the research-oriented international biopharmaceutical group, signed the Manifesto Against Gender-Based Violence with the CGIL, CISL, and UIL trade unions.
Inspired by the EU[1] and Istanbul[2] Conventions, the Manifesto aims to encourage all Group employees to adopt respectful and considerate behaviour, transparently communicating the necessary actions that must be taken in the event of any situations of violence in the workplace. The document is currently in force in Italy and – since it is the result of Chiesi’s global strategy on these issues – will soon be extended to its 30 Affiliates worldwide.
“Trust and mutual respect are two of the elements that underpin our work and are at the heart of this important manifesto. We are committed to taking concrete actions in line with the Group’s values to ensure that everyone has an opportunity to grow in their career, valuing diversity and talent. At Chiesi, it is essential that everyone can fully express themselves, finding a good balance between work and private life. If necessary, we are ready to provide the essential support to deal with any situation, including the most critical” commented Giacomo Mazzariello, Chief Human Resources Officer at the Chiesi Group.
As a Benefit Corporation and a certified B Corp, Chiesi has always been committed to people’s well-being and is opposed to all forms of discrimination. The Group, which was named one of the “Best Workplaces 2022” by Great Place to Work, strives, through concrete measures, to create a diversity-conscious work environment that values an inclusive and open approach in its everyday operations.
“This manifesto comes from far away, it is also the fruit of an important agreement signed on the occasion of the additional contract, which in 2020 committed the parties to sharing the will to build a path to prevent and combat gender-based violence, implementing joint initiatives. It represents a cultural evolution and concrete support to workers, a beautiful message that starts in Parma and reaches all the Group’s Affiliates. But what will make the difference is the signal that this document sends out, loud and clear, namely that there is a strong sharing of common objectives, which will not fail to raise awareness and increase vigilance on a phenomenon that concerns us all, and which must be taken care of collectively” - stated Marco Todeschi FILCTEM CGIL, Germano Giraud FEMCA CISL, and Sarah Leonelli UILTEC UIL, together with the company RSU.
Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. Since 2019 Chiesi is certified B Corp, meaning that its sustainability efforts are measured and assessed by the most ambitious global standards. The company aims at becoming net-zero by 2035.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
Contacts for media:
Alessio Pappagallo
Press Office Manager
Tel: +39 339 5897483
Email a.pappagallo@chiesi.com
[1] https://oeil.secure.europarl.europa.eu/oeil/popups/summary.do?id=1651109&t=e&l=en
[2] https://www.coe.int/en/web/conventions/full-list?module=treaty-detail&treatynum=210
